Beijing, Shanghai & Boston, Mar. 17, 2023 — Jacobio Pharma (1167.HK) has received IND (Investigational New Drug) approval of its self-developed drug GUE inhibitor JAB-24114 from the Center for Drug Evaluation (CDE) of China. Jacobio plans to initiate a Phase I/IIa clinical trial in the China.
Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways such as TCA cycles, nucleotide synthesis, purine synthesis and amino acid synthesis. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. Preclinical in vivo study exhibited that JAB-24114 can effectively inhibit tumor growth in multiple animal models.
JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors. Jacobio has self-developed SHP2 inhibitors (JAB-3312 and JAB-3068), KRAS G12C inhibitor Glecirasib (JAB-21822), and KRASmulti inhibitor (JAB-23400), which have potential to provide more combination therapies to patients.
Jacobio is committed to developing global first-in-class drugs, and key programs are targeting among the top three worldwide. Currently there is only one program in the Phase I clinical stage in respective drug class globally.
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.